An Open-label Phase I/IIa Clinical Trial of 11β-HSD1 Inhibitor for Cushing's Syndrome and Autonomous Cortisol Secretion

11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors demonstrate antimetabolic and antisarcopenic effects in Cushing's syndrome (CS) and autonomous cortisol secretion (ACS) patients. To confirm the efficacy and safety of S-707106 (11β-HSD1 inhibitor) administered to CS and ACS patients...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The journal of clinical endocrinology and metabolism 2021-09, Vol.106 (10), p.e3865-e3880
Hauptverfasser:	Oda, Satoko, Ashida, Kenji, Uchiyama, Makiko, Sakamoto, Shohei, Hasuzawa, Nao, Nagayama, Ayako, Wang, Lixiang, Nagata, Hiromi, Sakamoto, Ryuichi, Kishimoto, Junji, Todaka, Koji, Ogawa, Yoshihiro, Nakanishi, Yoichi, Nomura, Masatoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	11-beta-Hydroxysteroid Dehydrogenase Type 1 - antagonists & inhibitors Adult Aged Aged, 80 and over Asymptomatic Diseases Cushing Syndrome - drug therapy Cushing Syndrome - metabolism Databases, Factual Enzyme Inhibitors - therapeutic use Female Humans Hydrocortisone - metabolism Japan Male Middle Aged Organic Chemicals - therapeutic use Paraneoplastic Endocrine Syndromes - drug therapy Paraneoplastic Endocrine Syndromes - metabolism Registries
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!